Clinical Trial: Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07783620) titled 'Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies' on Aug. 21.

Brief Summary: The purpose of this research is to study the safety and effectiveness of investigational antibodies attacking certain areas on the surface of cancer cells so that the body can kill the cancer cells. The antibodies will be made in a laboratory from cells taken from each subject's tumor so they will be made specifically per subject.

The first step is to take blood and tumor samples so that the laboratory can produce antibodies specific to each subject's ...